Tags : Exclusive

BMS Signs an Exclusive Worldwide License Agreement with Dragonfly Therapeutics

Shots: Dragonfly to receive $475M as up front and is eligible to receive development, regulatory and commercial milestones in addition to 24% royalties on global sales of the therapy. BMS to get exclusive WW license to Dragonfly’s IL-12 investigational immunotherapy program, including its extended half-life cytokine DF6002 BMS will be responsible for the development & […]Read More

Zai Lab Signs an Exclusive License Agreement with Turning Point

Shots: Turning Point to receive $25M as upfront, $151M as development, regulatory and commercial milestones along with royalties on sales of repotrectinib in Greater China. Zai Lab to get exclusive rights to develop and commercialize repotrectinib in Greater China including China, Hong Kong, Macau, and Taiwan Zai Lab anticipates opening additional sites for the TRIDENT-1 […]Read More

BMS Signs an Exclusive Option to License Agreement with Dragonfly

Shots: Dragonfly to receive $55M upfront, additional payments for development, regulatory and sales milestones plus royalties on sales of approved products. BMS to get exclusive option to license exclusive worldwide IPR for multiple candidates developed using Dragonfly’s platform for multiple new targets The focus of the agreement is to expand the collaboration b/w the companies […]Read More

Sarepta Signs an Exclusive Worldwide License with Hansa to Develop

Shots: Hansa to receive $10M up front, up to $397.5M as development, regulatory & commercial milestones. Hansa will book all sales of therapy and will get royalties on gene therapy sales that arises from treating Ab-positive patients enabled through imlifidase pre-treatment Sarepta get an exclusive WW license to develop and promote imlifidase as a pre-treatment […]Read More

AbbVie Signs an Exclusive Research and Option to License Agreement

Shots: Sosei to receive ~$32M as upfront and ~$377M as option fees, development, and commercial milestones along with royalties on global sales of therapies. AbbVie to get an option to expand the collaboration up to a total of four therapies that modulate GPCR Sosei will leverage its StaR technology and GPCR-focused SBDD capabilities and fund […]Read More

AbbVie Signs an Exclusive Worldwide Option and License Agreement with

Shots: Alpine to receive $60M up front, ~$805M as option exercise fee, development, regulatory and commercial milestones along with royalties on net sales of ALPN-101 AbbVie to get an option to exclusively license ALPN-101, following exercising the option, AbbVie will conduct all future clinical development, manufacturing, and commercialization activities for ALPN-101 During the option period, […]Read More

Takeda Signs an Exclusive License and Research Agreement with Debiopharm

Shots: Takeda will screen & optimize compounds derived from Debiopharm’s Debio 1454M program to identify candidates for further development to treat IBD and other GI disorders Takeda will pursue the development of a novel preclinical narrow spectrum microbiome remodeling program. The candidates will be evaluated for their effectiveness against specific disease-causing microorganisms while preserving the […]Read More